These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1909485)

  • 21. A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease.
    Frankel JP; Kempster PA; Stibe CM; Eatough VM; Nathanson M; Lees AJ; Stern GM
    Clin Neuropharmacol; 1989 Oct; 12(5):448-51. PubMed ID: 2514981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience with selegiline and levodopa in advanced Parkinson's disease.
    Lieberman A; Fazzini E
    Acta Neurol Scand Suppl; 1991; 136():66-9. PubMed ID: 1801539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK
    Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
    [No Abstract]   [Full Text] [Related]  

  • 24. The effect of deprenyl washout in patients with long-standing Parkinson's disease.
    Djaldetti R; Ziv I; Melamed E
    J Neural Transm (Vienna); 2002 May; 109(5-6):797-803. PubMed ID: 12111469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
    Bravi D; Anderson JJ; Dagani F; Davis TL; Ferrari R; Gillespie M; Chase TN
    Mov Disord; 1992; 7(3):228-31. PubMed ID: 1620140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
    Takahashi M; Yuasa R; Imai T; Tachibana H; Yorifuji S; Nakamura Y; Ogawa N
    Intern Med; 1994 Sep; 33(9):517-24. PubMed ID: 8000101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease.
    Rinne UK
    Neurology; 1989 Mar; 39(3):336-9. PubMed ID: 2927639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selegiline and cognitive function in Parkinson's disease.
    Hietanen MH
    Acta Neurol Scand; 1991 Nov; 84(5):407-10. PubMed ID: 1776388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study.
    Battistin L; Bardin PG; Ferro-Milone F; Ravenna C; Toso V; Reboldi G
    Acta Neurol Scand; 1999 Jan; 99(1):36-42. PubMed ID: 9925236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-deprenyl as an adjunct to low-dose bromocriptine in early Parkinson's disease: a short-term, double-blind, and prospective follow-up study.
    Calzetti S; Negrotti A; Cassio A
    Clin Neuropharmacol; 1995 Jun; 18(3):250-7. PubMed ID: 8635183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early combination with deprenyl: a retrospective analysis.
    Fornadi F; Ulm G
    Adv Neurol; 1990; 53():437-40. PubMed ID: 2122650
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.
    Elizan TS; Moros DA; Yahr MD
    Arch Neurol; 1991 Jan; 48(1):31-4. PubMed ID: 1898848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.
    Stocchi F; Ruggieri S; Antonini A; Baronti F; Brughitta G; Bellantuono P; Bravi D; Agnoli A
    J Neural Transm Suppl; 1988; 27():27-33. PubMed ID: 3165437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. L-deprenyl in the treatment of Parkinson's disease.
    Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
    J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA; Burns RS; Calne DB
    Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lisuride combined with levodopa in advanced Parkinson disease.
    Lieberman AN; Goldstein M; Leibowitz M; Neophytides A; Gopinathan G; Walker R; Pact V
    Neurology; 1981 Nov; 31(11):1466-9. PubMed ID: 7031504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of a low-dose subcutaneous lisuride infusion in Parkinson's disease.
    Hayashi R; Tako K; Makishita H; Koyama J; Yanagisawa N
    Intern Med; 1998 May; 37(5):444-8. PubMed ID: 9652898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Adv Neurol; 1990; 53():431-5. PubMed ID: 2122649
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.